Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

1.320 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
30 31 Next >
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Great Start to its 2022 R&D Programs Following Independent Review Board Approval
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Featured in EDGE Podcast Interview
Via CannabisNewsWire
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Comments on Study Examining Cannabinoids and SARS-CoV-2
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Provides Comments Regarding Study Examining Cannabinoids and SARS-CoV-2
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Leveraging DehydraTECH(TM) for More Effective Oral Medicine
Via Investor Brand Network
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2" KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company"... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) to Deliver More Effective Oral Medicine
Via Investor Brand Network
After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
Via Investor Brand Network
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Independent Review Board Approval for Its Most Ambitious, Comprehensive Human Study Yet
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
Lexaria Bioscience Increases Investor Visibility with SRAX
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Increases Investor Visibility with SRAX (NASDAQ: SRAX)
Via Investor Brand Network
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Increases Investor Visibility with SRAX Inc. (NASDAQ: SRAX)
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals One Drug Class at a Time
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Approval from Independent Review for DehydraTECH-CBD Study
Via Investor Brand Network
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.